{"id":689790,"date":"2022-09-28T09:18:08","date_gmt":"2022-09-28T13:18:08","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-to-present-new-clinical-data-at-the-2022-san-antonio-breast-cancer-symposium-december-6th-and-7th\/"},"modified":"2022-09-28T09:18:08","modified_gmt":"2022-09-28T13:18:08","slug":"briacell-to-present-new-clinical-data-at-the-2022-san-antonio-breast-cancer-symposium-december-6th-and-7th","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-to-present-new-clinical-data-at-the-2022-san-antonio-breast-cancer-symposium-december-6th-and-7th\/","title":{"rendered":"BriaCell to Present New Clinical Data at the 2022 San Antonio Breast Cancer Symposium\u00ae December 6th and 7th"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">PHILADELPHIA and VANCOUVER, British Columbia, Sept.  28, 2022  (GLOBE NEWSWIRE) &#8212; <strong>BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d)<\/strong>, a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, is pleased to announce that its lead product candidate, Bria-IMT\u2122, will be featured in three posters during the 2022 San Antonio Breast Cancer Symposium\u00ae taking place December 6-10, 2022\u00a0at the Henry B. Gonzalez Convention Center in San Antonio, Texas.<\/p>\n<p align=\"justify\">\u201cOur mission is to find solutions for advanced breast cancer patients who do not respond to current treatments. We are thrilled for the opportunity to share our clinical findings with clinicians who treat similar, difficult-to-treat patients,\u201d stated Dr. Bill Williams, BriaCell\u2019s President &amp; CEO.<\/p>\n<p align=\"justify\">All poster presentations will be held at<strong>\u00a0<\/strong>Hall 1, Henry B. Gonzalez Convention Center, 900 E. Market Street, San Antonio, TX 78205 U.S.A. Details on the poster presentations are as follows:<\/p>\n<p align=\"left\">\n        <strong>Poster ID:<\/strong>\u00a0P1-05-28<br \/><strong>Date:<\/strong> Tuesday, December 6, 2022<br \/><strong>Time:<\/strong> 5:00 PM &#8211;\u00a06:15 PM<\/p>\n<p align=\"left\">\n        <strong>Poster ID:<\/strong>\u00a0P3-07-12 <br \/><strong>Poster ID:<\/strong>\u00a0P3-06-08<br \/><strong>Date:<\/strong> Wednesday, December 7, 2022<br \/><strong>Time:<\/strong> 5:00 PM &#8211;\u00a06:15 PM<\/p>\n<p align=\"justify\">Following the presentations, copies of the posters will be posted on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=cwKjquUz2IVXyODXbc8LtSKLvA8OlobSFAXB4hFQlLqYR9CoXyZMlloaA4Gutdm4AiypBdSKiTIipvUiUjBS-O-5hOw1NrBoCzCWnh18aRxmdygMdNG7J1nVXUJikvOij-1y_jDZql7-m14D3pz3gA==\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/briacell.com\/scientific-publications\/<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>About BriaCell Therapeutics Corp.<\/strong>\n      <\/p>\n<p align=\"justify\">BriaCell is an immuno-oncology-focused biotechnology company developing targeted and effective approaches for the management of cancer. More information is available at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=cwKjquUz2IVXyODXbc8LtQJvF6hM8keGzksHApOtrvUJBBSduBoJDEKuYE1DpwCJxXNYNiMqxdx3gWH9_EGhwg==\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/briacell.com\/<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Safe Harbor<\/strong>\n      <\/p>\n<p align=\"justify\">This press release contains \u201cforward-looking statements\u201d that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontemplate,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cseek,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201ctarget,\u201d \u201caim,\u201d \u201cshould,\u201d \u201cwill,\u201d \u201cwould,\u201d or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on BriaCell\u2019s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading \u201cRisks and Uncertainties\u201d in the Company&#8217;s most recent Management\u2019s Discussion and Analysis, under the heading &#8220;Risk Factors&#8221; in the Company&#8217;s most recent Annual Information Form, and under \u201cRisks and Uncertainties\u201d in the Company&#8217;s other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company&#8217;s profiles on SEDAR at www.sedar.com and on EDGAR at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=XOnE8D3x815bEXA-cZnI85szBvmkG4EwqbWVPZNRlYzBqdD7r-QtPSjRV6yw6A3hGUS4YXIZqCLIvBvJjURV2w==\" rel=\"nofollow noopener\" target=\"_blank\"><strong>www.sec.gov<\/strong><\/a>. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.<\/p>\n<p align=\"justify\">Neither Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.<\/p>\n<p align=\"left\">\n        <strong>Contact Information<\/strong>\n      <\/p>\n<p align=\"left\">\n        <strong>Company Contact:<\/strong><br \/>\n        <br \/>William V. Williams, MD<br \/>President &amp; CEO<br \/>1-888-485-6340<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=MMKxp1Juh5Tuq0Y7VIlUkyF2swRq775qhAg6YSEz3wm5edvSmYfKPPuTys1aMAkUiJOfGujy50gbvuQxyBe28Q==\" rel=\"nofollow noopener\" target=\"_blank\">info@briacell.com<\/a>\u00a0<\/p>\n<p align=\"left\">\n        <strong>Media Relations:<\/strong><br \/>\n        <br \/>Jules Abraham<br \/>Director of Public Relations<br \/>CORE IR<br \/>917-885-7378<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=aBk0EDJkpjYlnXM-ZVrIOTsTl2vJzJXRCwa0swXAJbfcxyQWCMrWZl4L5NwQfw0EcVxwIBHUme9T3xyB-9sz_Q==\" rel=\"nofollow noopener\" target=\"_blank\">julesa@coreir.com<\/a><\/p>\n<p align=\"left\">\n        <strong>Investor Relations Contact:<\/strong><br \/>\n        <br \/>CORE IR<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ayzGPwzgn1bzlMRFNEOvRwFK_gde3gDkvWf-R-Kaw7JIVppCJvK19RSNcml68W7OiADMeht5psrXLv39nKJwibgFPC9kUPasFk9BZex-lP4=\" rel=\"nofollow noopener\" target=\"_blank\">investors@briacell.com<\/a><\/p>\n<p>\u00a0<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1NDYwMyM1MTc1Mzk0IzIwOTA2NTg=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/NTAyZmQ4MGQtYzFhMC00NmU2LWFlNDItMzU5YWIyMDE1ZWEzLTExMDIyMjk=\/tiny\/BriaCell-Therapeutics-Corp-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>PHILADELPHIA and VANCOUVER, British Columbia, Sept. 28, 2022 (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, is pleased to announce that its lead product candidate, Bria-IMT\u2122, will be featured in three posters during the 2022 San Antonio Breast Cancer Symposium\u00ae taking place December 6-10, 2022\u00a0at the Henry B. Gonzalez Convention Center in San Antonio, Texas. \u201cOur mission is to find solutions for advanced breast cancer patients who do not respond to current treatments. We are thrilled for the opportunity to share our clinical findings with clinicians who treat similar, difficult-to-treat patients,\u201d stated Dr. Bill Williams, BriaCell\u2019s President &amp; CEO. All poster presentations will &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-to-present-new-clinical-data-at-the-2022-san-antonio-breast-cancer-symposium-december-6th-and-7th\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;BriaCell to Present New Clinical Data at the 2022 San Antonio Breast Cancer Symposium\u00ae December 6th and 7th&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-689790","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>BriaCell to Present New Clinical Data at the 2022 San Antonio Breast Cancer Symposium\u00ae December 6th and 7th - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-to-present-new-clinical-data-at-the-2022-san-antonio-breast-cancer-symposium-december-6th-and-7th\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BriaCell to Present New Clinical Data at the 2022 San Antonio Breast Cancer Symposium\u00ae December 6th and 7th - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PHILADELPHIA and VANCOUVER, British Columbia, Sept. 28, 2022 (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, is pleased to announce that its lead product candidate, Bria-IMT\u2122, will be featured in three posters during the 2022 San Antonio Breast Cancer Symposium\u00ae taking place December 6-10, 2022\u00a0at the Henry B. Gonzalez Convention Center in San Antonio, Texas. \u201cOur mission is to find solutions for advanced breast cancer patients who do not respond to current treatments. We are thrilled for the opportunity to share our clinical findings with clinicians who treat similar, difficult-to-treat patients,\u201d stated Dr. Bill Williams, BriaCell\u2019s President &amp; CEO. All poster presentations will &hellip; Continue reading &quot;BriaCell to Present New Clinical Data at the 2022 San Antonio Breast Cancer Symposium\u00ae December 6th and 7th&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-to-present-new-clinical-data-at-the-2022-san-antonio-breast-cancer-symposium-december-6th-and-7th\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-28T13:18:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1NDYwMyM1MTc1Mzk0IzIwOTA2NTg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-to-present-new-clinical-data-at-the-2022-san-antonio-breast-cancer-symposium-december-6th-and-7th\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-to-present-new-clinical-data-at-the-2022-san-antonio-breast-cancer-symposium-december-6th-and-7th\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"BriaCell to Present New Clinical Data at the 2022 San Antonio Breast Cancer Symposium\u00ae December 6th and 7th\",\"datePublished\":\"2022-09-28T13:18:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-to-present-new-clinical-data-at-the-2022-san-antonio-breast-cancer-symposium-december-6th-and-7th\\\/\"},\"wordCount\":544,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-to-present-new-clinical-data-at-the-2022-san-antonio-breast-cancer-symposium-december-6th-and-7th\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1NDYwMyM1MTc1Mzk0IzIwOTA2NTg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-to-present-new-clinical-data-at-the-2022-san-antonio-breast-cancer-symposium-december-6th-and-7th\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-to-present-new-clinical-data-at-the-2022-san-antonio-breast-cancer-symposium-december-6th-and-7th\\\/\",\"name\":\"BriaCell to Present New Clinical Data at the 2022 San Antonio Breast Cancer Symposium\u00ae December 6th and 7th - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-to-present-new-clinical-data-at-the-2022-san-antonio-breast-cancer-symposium-december-6th-and-7th\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-to-present-new-clinical-data-at-the-2022-san-antonio-breast-cancer-symposium-december-6th-and-7th\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1NDYwMyM1MTc1Mzk0IzIwOTA2NTg=\",\"datePublished\":\"2022-09-28T13:18:08+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-to-present-new-clinical-data-at-the-2022-san-antonio-breast-cancer-symposium-december-6th-and-7th\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-to-present-new-clinical-data-at-the-2022-san-antonio-breast-cancer-symposium-december-6th-and-7th\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-to-present-new-clinical-data-at-the-2022-san-antonio-breast-cancer-symposium-december-6th-and-7th\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1NDYwMyM1MTc1Mzk0IzIwOTA2NTg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1NDYwMyM1MTc1Mzk0IzIwOTA2NTg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-to-present-new-clinical-data-at-the-2022-san-antonio-breast-cancer-symposium-december-6th-and-7th\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BriaCell to Present New Clinical Data at the 2022 San Antonio Breast Cancer Symposium\u00ae December 6th and 7th\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BriaCell to Present New Clinical Data at the 2022 San Antonio Breast Cancer Symposium\u00ae December 6th and 7th - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-to-present-new-clinical-data-at-the-2022-san-antonio-breast-cancer-symposium-december-6th-and-7th\/","og_locale":"en_US","og_type":"article","og_title":"BriaCell to Present New Clinical Data at the 2022 San Antonio Breast Cancer Symposium\u00ae December 6th and 7th - Market Newsdesk","og_description":"PHILADELPHIA and VANCOUVER, British Columbia, Sept. 28, 2022 (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, is pleased to announce that its lead product candidate, Bria-IMT\u2122, will be featured in three posters during the 2022 San Antonio Breast Cancer Symposium\u00ae taking place December 6-10, 2022\u00a0at the Henry B. Gonzalez Convention Center in San Antonio, Texas. \u201cOur mission is to find solutions for advanced breast cancer patients who do not respond to current treatments. We are thrilled for the opportunity to share our clinical findings with clinicians who treat similar, difficult-to-treat patients,\u201d stated Dr. Bill Williams, BriaCell\u2019s President &amp; CEO. All poster presentations will &hellip; Continue reading \"BriaCell to Present New Clinical Data at the 2022 San Antonio Breast Cancer Symposium\u00ae December 6th and 7th\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-to-present-new-clinical-data-at-the-2022-san-antonio-breast-cancer-symposium-december-6th-and-7th\/","og_site_name":"Market Newsdesk","article_published_time":"2022-09-28T13:18:08+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1NDYwMyM1MTc1Mzk0IzIwOTA2NTg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-to-present-new-clinical-data-at-the-2022-san-antonio-breast-cancer-symposium-december-6th-and-7th\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-to-present-new-clinical-data-at-the-2022-san-antonio-breast-cancer-symposium-december-6th-and-7th\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"BriaCell to Present New Clinical Data at the 2022 San Antonio Breast Cancer Symposium\u00ae December 6th and 7th","datePublished":"2022-09-28T13:18:08+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-to-present-new-clinical-data-at-the-2022-san-antonio-breast-cancer-symposium-december-6th-and-7th\/"},"wordCount":544,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-to-present-new-clinical-data-at-the-2022-san-antonio-breast-cancer-symposium-december-6th-and-7th\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1NDYwMyM1MTc1Mzk0IzIwOTA2NTg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-to-present-new-clinical-data-at-the-2022-san-antonio-breast-cancer-symposium-december-6th-and-7th\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-to-present-new-clinical-data-at-the-2022-san-antonio-breast-cancer-symposium-december-6th-and-7th\/","name":"BriaCell to Present New Clinical Data at the 2022 San Antonio Breast Cancer Symposium\u00ae December 6th and 7th - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-to-present-new-clinical-data-at-the-2022-san-antonio-breast-cancer-symposium-december-6th-and-7th\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-to-present-new-clinical-data-at-the-2022-san-antonio-breast-cancer-symposium-december-6th-and-7th\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1NDYwMyM1MTc1Mzk0IzIwOTA2NTg=","datePublished":"2022-09-28T13:18:08+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-to-present-new-clinical-data-at-the-2022-san-antonio-breast-cancer-symposium-december-6th-and-7th\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/briacell-to-present-new-clinical-data-at-the-2022-san-antonio-breast-cancer-symposium-december-6th-and-7th\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-to-present-new-clinical-data-at-the-2022-san-antonio-breast-cancer-symposium-december-6th-and-7th\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1NDYwMyM1MTc1Mzk0IzIwOTA2NTg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1NDYwMyM1MTc1Mzk0IzIwOTA2NTg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-to-present-new-clinical-data-at-the-2022-san-antonio-breast-cancer-symposium-december-6th-and-7th\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"BriaCell to Present New Clinical Data at the 2022 San Antonio Breast Cancer Symposium\u00ae December 6th and 7th"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/689790","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=689790"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/689790\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=689790"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=689790"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=689790"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}